Market Closed -
Australian S.E.
01:05:46 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
0.082
AUD
|
0.00%
|
|
-2.38%
|
-39.26%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
20.65
|
18.13
|
7.959
|
178.9
|
246.2
|
90.11
|
Enterprise Value (EV)
1 |
12.83
|
13.36
|
6.159
|
176.6
|
238.8
|
86.03
|
P/E ratio
|
-9.11
x
|
-7.11
x
|
-1.98
x
|
-24.8
x
|
-27.4
x
|
-10.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
17,647,412
x
|
79,591,490
x
|
161,407,158
x
|
101,422,775
x
|
29,108,385
x
|
EV / Revenue
|
-
|
13,002,383
x
|
61,586,280
x
|
159,356,295
x
|
98,363,837
x
|
27,789,011
x
|
EV / EBITDA
|
-8.03
x
|
-5.1
x
|
-1.55
x
|
-27.1
x
|
-27.4
x
|
-10.3
x
|
EV / FCF
|
-10.5
x
|
-6.1
x
|
-4.46
x
|
-59.4
x
|
-72.7
x
|
-20.9
x
|
FCF Yield
|
-9.56%
|
-16.4%
|
-22.4%
|
-1.68%
|
-1.37%
|
-4.79%
|
Price to Book
|
2.49
x
|
3.1
x
|
4.32
x
|
105
x
|
33.4
x
|
15.3
x
|
Nbr of stocks (in thousands)
|
100,750
|
100,750
|
100,750
|
202,171
|
214,082
|
219,793
|
Reference price
2 |
0.2050
|
0.1800
|
0.0790
|
0.8850
|
1.150
|
0.4100
|
Announcement Date
|
8/31/18
|
8/29/19
|
8/31/20
|
8/31/21
|
8/29/22
|
8/31/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
1.028
|
0.1
|
1.109
|
2.427
|
3.096
|
EBITDA
1 |
-1.597
|
-2.622
|
-3.98
|
-6.518
|
-8.724
|
-8.345
|
EBIT
1 |
-1.629
|
-2.687
|
-4.061
|
-6.625
|
-8.818
|
-8.446
|
Operating Margin
|
-
|
-261.5%
|
-4,061.45%
|
-597.65%
|
-363.29%
|
-272.81%
|
Earnings before Tax (EBT)
1 |
-1.753
|
-2.546
|
-4.023
|
-6.612
|
-8.794
|
-8.218
|
Net income
1 |
-1.753
|
-2.546
|
-4.023
|
-6.612
|
-8.794
|
-8.218
|
Net margin
|
-
|
-247.77%
|
-4,022.98%
|
-596.49%
|
-362.26%
|
-265.44%
|
EPS
2 |
-0.0225
|
-0.0253
|
-0.0399
|
-0.0357
|
-0.0419
|
-0.0379
|
Free Cash Flow
1 |
-1.226
|
-2.192
|
-1.38
|
-2.972
|
-3.283
|
-4.124
|
FCF margin
|
-
|
-213.3%
|
-1,380.36%
|
-268.07%
|
-135.24%
|
-133.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/31/18
|
8/29/19
|
8/31/20
|
8/31/21
|
8/29/22
|
8/31/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7.83
|
4.77
|
1.8
|
2.27
|
7.43
|
4.08
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.23
|
-2.19
|
-1.38
|
-2.97
|
-3.28
|
-4.12
|
ROE (net income / shareholders' equity)
|
-36.1%
|
-36%
|
-105%
|
-373%
|
-194%
|
-124%
|
ROA (Net income/ Total Assets)
|
-20.4%
|
-22.9%
|
-57.2%
|
-145%
|
-95.8%
|
-65.4%
|
Assets
1 |
8.611
|
11.13
|
7.033
|
4.564
|
9.18
|
12.56
|
Book Value Per Share
2 |
0.0800
|
0.0600
|
0.0200
|
0.0100
|
0.0300
|
0.0300
|
Cash Flow per Share
2 |
0.0800
|
0.0500
|
0.0200
|
0.0100
|
0.0400
|
0.0200
|
Capex
1 |
0.01
|
0.11
|
0.05
|
0.07
|
0.03
|
0.1
|
Capex / Sales
|
-
|
10.73%
|
45.54%
|
6.16%
|
1.11%
|
3.2%
|
Announcement Date
|
8/31/18
|
8/29/19
|
8/31/20
|
8/31/21
|
8/29/22
|
8/31/23
|
|
1st Jan change
|
Capi.
|
---|
| -39.26% | 13.34M | | -16.10% | 11.41B | | -30.20% | 2.3B | | -14.31% | 2.16B | | -26.03% | 1.56B | | +36.95% | 1.19B | | -2.40% | 760M | | -19.00% | 506M | | -38.57% | 444M | | +13.72% | 339M |
Bio Diagnostics & Testing
|